Atropine sulfate; diphenoxylate hydrochloride - Generic Drug Details

What are the generic drug sources for atropine sulfate; diphenoxylate hydrochloride and what is the scope of patent protection?

Atropine sulfate; diphenoxylate hydrochloride is the generic ingredient in ten branded drugs marketed by Scherer Rp, Medpointe Pharm Hlc, Hikma, Alpharma Us Pharms, Gd Searle Llc, Md Pharm, Able, Ani Pharms, Ascot, Chartwell Rx, Dr Reddys Labs Sa, Fosun Pharma, Heather, Inwood Labs, Kv Pharm, Lannett, Leading, Lederle, Parke Davis, Pharmobedient, Pvt Form, R And S Pharma, Roxane, Specgx Llc, Strides Pharma Intl, Sun Pharm Industries, Unichem, Upsher Smith Labs, Usl Pharma, Valeant Pharm Intl, Watson Labs, Winder Labs Llc, Vangard, Superpharm, Pfizer, and Halsey, and is included in thirty-nine NDAs. Additional information is available in the individual branded drug profile pages.

Twenty suppliers are listed for this compound.

Summary for atropine sulfate; diphenoxylate hydrochloride

US Patents:	0
Tradenames:	10
Applicants:	36
NDAs:	39
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	5
Clinical Trials:	1
DailyMed Link:	atropine sulfate; diphenoxylate hydrochloride at DailyMed

Recent Clinical Trials for atropine sulfate; diphenoxylate hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Napo Pharmaceuticals, Inc.	Phase 2
University of California, San Francisco	Phase 2
Puma Biotechnology, Inc.	Phase 2

See all atropine sulfate; diphenoxylate hydrochloride clinical trials

Pharmacology for atropine sulfate; diphenoxylate hydrochloride

Drug Class	Anticholinergic Antidiarrheal Cholinergic Muscarinic Antagonist
Mechanism of Action	Cholinergic Antagonists Cholinergic Muscarinic Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for atropine sulfate; diphenoxylate hydrochloride

A03BA	Belladonna alkaloids, tertiary amines
A03B	BELLADONNA AND DERIVATIVES, PLAIN
A03	DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A	Alimentary tract and metabolism

A07DA	Antipropulsives
A07D	ANTIPROPULSIVES
A07	ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A	Alimentary tract and metabolism

S01FA	Anticholinergics
S01F	MYDRIATICS AND CYCLOPLEGICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

US Patents and Regulatory Information for atropine sulfate; diphenoxylate hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Parke Davis	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	atropine sulfate; diphenoxylate hydrochloride	TABLET;ORAL	087131-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Kv Pharm	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	atropine sulfate; diphenoxylate hydrochloride	TABLET;ORAL	085659-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Watson Labs	DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE	atropine sulfate; diphenoxylate hydrochloride	TABLET;ORAL	085876-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Market Dynamics and Financial Trajectory for Atropine Sulfate and Diphenoxylate Hydrochloride

Last updated: February 15, 2026

---

What Are the Current Market Positions for Atropine Sulfate and Diphenoxylate Hydrochloride?

Atropine sulfate and diphenoxylate hydrochloride are pharmaceuticals with distinct therapeutic indications. Atropine sulfate, a muscarinic receptor antagonist, is primarily used in ophthalmology, as a pre-anesthetic, and to treat bradycardia. Diphenoxylate hydrochloride, an opioid with antiperistaltic effects, is approved for diarrhea management under the brand name Lomotil.

The combined market for these drugs is limited, with atropine sulfate's primary use in hospital and specialty settings, and diphenoxylate hydrochloride largely in outpatient treatment.

Market size estimates:

• Global atropine sulfate market: USD 300-400 million (2022).
• Diphenoxylate hydrochloride market: USD 100-150 million (2022).

Market drivers include aging populations, increased prevalence of gastrointestinal and cardiac conditions, and ongoing use in anesthetic procedures.

How Is the Patent Landscape Evolving?

Atropine sulfate: It is off-patent globally, with several generic manufacturers producing it. Limited patent activity exists around delivery methods or formulations.

Diphenoxylate hydrochloride: Also off-patent, with patent protection expired decades ago. There is ongoing interest in developing combination formulations to extend market exclusivity.

Rare patent filings focus on extended-release formulations, new delivery systems, or combination drugs, potentially offering extension of market exclusivity.

What Are the Key Factors Influencing Market Growth?

1. Regulatory Dynamics:

   • Both drugs face regulatory re-approvals for new indications or formulations.
   • New formulations with improved bioavailability or reduced side effects could promote growth.

2. Healthcare Trends:

   • Rising geriatric populations increase demand for cardiac and GI therapies.
   • Increased emphasis on outpatient and minimally invasive procedures enhances need for formulations suited for quick administration.

3. Patent and Exclusivity Timelines:

   • As currently off-patent, market entry of generics is dominant.
   • Any new formulation can seek data exclusivity, impacting generics' timing.

4. Competitive Landscape:

   • Large generic pharmaceutical firms hold the existing market share.
   • Innovator companies are likely to pursue niche formulations or combinations.

What Is the Financial Outlook for Investment and R&D?

Revenue trajectories:

• Given the mature status, growth hinges on new formulations or off-label expansion.
• Projects aiming at extended-release formulations or novel delivery methods could generate USD 50-100 million annually per product in niche markets.

R&D investments:

• Development costs for reformulations range USD 10-20 million.
• Clinical trials are generally brief due to existing safety profiles, reducing time-to-market.

Market entry risks:

• Regulatory hurdles.
• Competition from existing generics.
• Limited scope for off-label use expansion.

Potential revenue gains from innovation:

• Niche formulations could command premiums of 10-20% over current prices.
• Strategic partnerships with specialty clinics or hospitals enhance revenue streams.

Future prospects:

• Limited pipeline activity due to age of drugs.
• Focus on combination therapies or new indications for existing formulations.

How Do External Factors Shape the Market?

Global health policies:

• Push for generic utilization reduces margins for proprietary formulations but opens opportunities for branded formulations with differentiated features.

Pricing regulations:

• Price caps in key markets like the US, EU, and Japan restrict revenue growth.
• In emerging markets, growth is driven by affordability and local manufacturing.

Supply chain considerations:

• Raw material availability, especially for atropine sulfate, is stable but susceptible to geopolitical factors.
• Diphenoxylate production depends on opioid supply policies, influencing pricing and availability.

---

Key Takeaways

• Both drugs are mature markets dominated by generics with historical sales stability.
• Opportunities for growth exist in reformulation with extended-release or combination formats.
• R&D investments are relatively modest, focusing on niche innovation.
• Regulatory and pricing environments pose risks to revenue expansion.
• External market factors, including demographics and healthcare policies, influence growth potential.

---

FAQs

1. Are there any upcoming patent protections or exclusivity periods for these drugs?
Most patents have expired; only new formulations with data exclusivity may offer temporary market advantages, typically up to 7 years for new patents or 5 years for regulatory exclusivity in many jurisdictions.

2. What key regulatory challenges exist for developing new formulations?
Regulatory agencies require demonstration of bioequivalence for generics and safety/effectiveness for new formulations, which may involve abbreviated or full clinical trials, depending on the region.

3. How does the competitive environment impact pricing strategies?
Generics dominate, leading to aggressive price competition. Innovative formulations with meaningful clinical advantages can command higher prices and margins.

4. Are there unmet medical needs for these drugs?
Limited, as the drugs are well-established. However, niche areas such as specific delivery methods or formulations for pediatric or geriatric populations present growth opportunities.

5. How are market trends likely to evolve in the next five years?
Market growth will primarily come from formulation innovations and strategic partnerships rather than new chemical entities, which are unlikely given the age of these drugs.

---

Citations

1. MarketWatch. "Atropine Sulfate Market Size and Forecast." 2022.
2. Grand View Research. "Diphenoxylate Hydrochloride Market Analysis." 2022.
3. U.S. Food and Drug Administration. "Guidance for Industry: Abbreviated New Drug Application." 2021.
4. GlobalData. "Pharmaceutical Patent Landscape and Trends." 2022.
5. IQVIA. "Global Pharmaceutical Markets Report." 2022.